TY - JOUR T1 - Predicting the Effectiveness of the Pfizer-BioNTech BNT162b2 Vaccine from SARS-CoV-2 Variants Neutralisation Data JF - medRxiv DO - 10.1101/2021.09.06.21263160 SP - 2021.09.06.21263160 AU - Oleg Volkov AU - Svetlana Borozdenkova AU - Alexander Gray Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/24/2021.09.06.21263160.abstract N2 - Modelling frameworks for vaccine protection are sorely needed to fight the Covid-19 pandemic with vaccines. We propose such a framework for the BNT162b2 and potentially other vaccines. It utilises correlates of protection based on live SARS-CoV-2 variants neutralising antibody titres from vaccinated individuals. We applied it to predict vaccine effectiveness in overall populations and age subgroups, following partial or full vaccination. It was validated by predicting effectiveness against D614G, B.1.1.7 (Alpha) and B.1.167.2 (Delta) variants. The predictions for Delta were 44.8% (22%, 69%) after one and 84.6% (64%, 97%) after two vaccine doses, which were close to the corresponding means, 45.6% and 85.5%, of observations in real-life effectiveness studies. Predictions for the other variants were also accurate. We also consider methods of safeguarding predictions against biases. Finally, we discuss implications for vaccination policies, such as decisions about doses and timing of vaccine boosters.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work received no external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The paper only used publicly available data collected externally.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and R code used for this paper will be freely available on or before 1 October 2021. https://github.com/spockoyno/pfizer_biontech_vaccine_paper ER -